Future clinical trials and regulatory activity..👇
Ventyx Biosciences
🔬 Initiate a Ph3 trial of VTX002 treating UC in H2 2024.
Lytix Biopharma
🔬 Initiate an investigator-led Ph2 study for a neoadjuvant in melanoma patients in H1 2024.
GRI Bio
🔬 Received UK-MHRA authorization to conduct Ph2a biomarker study evaluating GRI-0621 in IPF.
PepGen
🔬 CTA cleared by the UK-MHRA to initiate Ph2 CONNECT2-EDO51 trial of PGN-EDO51 for the treatment of DMD.
Nektar Therapeutics
🔬 Initiated a Ph2b study evaluating Rezpegaldesleukin in patients with alopecia areata.
Atara Biotherapeutics
🔬 FDA cleared IND application for a Ph1 trial of ATA3219 as treatment for lupus nephritis in H2 2024.
Cullinan Oncology
🔬 IND application cleared for a Ph1 trial of CLN-619 for relapsed/refractory multiple myeloma.
Precision BioSciences & iECURE
🔬 UK-MHRA approved to expand the Ph1/2 trial of ARCUS gene editing program in OTC deficiency.
Quoin Pharmaceuticals
🔬 Received FDA clearance to recruit teen subjects into both ongoing Netherton syndrome clinical studies.
Oncolytics Biotech
🔬 Protocol amendment filed to initiate a new pancreatic cancer GOBLET cohort supported by PanCAN.
Achieve Life Sciences
🔬 Open-label exposure trial expected to initiate in Q2 2024.
Crossbow Therapeutics
🔬 Selected first development candidate (CBX-250) from portfolio of next-generation T-cell engagers.
Iovance Biotherapeutics
📋 FDA lifted clinical hold on the IOV-LUN-202 registrational trial in NSCLC.
Calliditas Therapeutics
📋 Granted additional seven year orphan drug exclusivity period for TARPEYO®.
Verastem Oncology
📋 FDA granted Orphan Drug Designation to Avutometinib +/- Defactinib in recurrent low-grade serous ovarian cancer.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Article History:
RF, DV (03/06/24)
Comments